Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (I): preparation and characterization
about
Nanomedicines based on recombinant fusion proteins for targeting therapeutic siRNA oligonucleotides.Magnetic nanoparticles for tumor imaging and therapy: a so-called theranostic system.Combination of antibody targeting and PTD-mediated intracellular toxin delivery for colorectal cancer therapyThe use of low molecular weight protamine chemical chimera to enhance monomeric insulin intestinal absorptionCell permeable cocaine esterases constructed by chemical conjugation and genetic recombination.Synthetic skin-permeable proteins enabling needleless immunization.Interaction of heparin with two synthetic peptides that neutralize the anticoagulant activity of heparin.Intracellular trafficking and exocytosis of a multi-component siRNA nanocomplex.Nose-to-brain delivery of macromolecules mediated by cell-penetrating peptidesChemically and biologically synthesized CPP-modified gelonin for enhanced anti-tumor activity.Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (II): in vitro evaluation of efficacy and toxicity.L-Asparaginase encapsulated intact erythrocytes for treatment of acute lymphoblastic leukemia (ALL).Cell-penetrating peptides meditated encapsulation of protein therapeutics into intact red blood cells and its application.Peptides used in the delivery of small noncoding RNA.Immobilized thermolysin for highly efficient production of low-molecular-weight protamine--an attractive cell-penetrating peptide for macromolecular drug delivery applications.High-Yield Synthesis of Monomeric LMWP(CPP)-siRNA Covalent Conjugate for Effective Cytosolic Delivery of siRNA.Intein-mediated site-specific synthesis of tumor-targeting protein delivery system: Turning PEG dilemma into prodrug-like feature.Precipitation and Neutralization of Heparin from Different Sources by Protamine Sulfate.Cell-penetrating chitosan/doxorubicin/TAT conjugates for efficient cancer therapy.
P2860
Q27692125-6AD804EE-D00E-4091-A791-F3C8FAF1A803Q34229309-0527F8BD-21A6-4092-9167-6985C7A5C882Q34616158-67DF67CF-979F-44D0-A156-F7AAFC5FC3E6Q34829819-FAD82A49-03C3-433E-A529-02419BD49073Q35952119-7F1C9938-46BF-4A7A-8D46-9673C815A6C1Q36345639-6FA5B13F-2A80-4886-8E0C-E786C1901CE8Q36857920-4098DB22-E56C-44C4-A82D-110BB49F0F76Q36957575-2E436CA3-8B99-43CB-AA53-191CF3FDA6CAQ37110643-ABE676CA-2A7F-4033-B998-E6289A80B562Q37361218-D14A22BF-51EF-4F81-80BB-792D0317EB06Q37361505-DB9BD69E-F4CF-4AC6-8154-29AA98AF8F2FQ37371369-75ABF7B9-B6F9-4777-8809-126F93B045ECQ37612333-6A25EEA7-14B8-4869-B6A2-509426D282A2Q38243361-F4CECD8B-7D39-4785-A637-D0DBC162D087Q38469048-F976F2C6-651C-4E0D-B9F7-B711E72E06D3Q38651811-E4C3FF0A-553A-4296-855B-0E0088DB1A56Q38942506-25FB60A3-A220-41AD-822E-40C56137053FQ42366867-CA3AB8DC-5578-41C9-96E4-41BBDCF2B789Q53463074-940D12F3-4981-4D62-8777-346454B3C006
P2860
Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (I): preparation and characterization
description
2001 nî lūn-bûn
@nan
2001 թուականին հրատարակուած գիտական յօդուած
@hyw
2001 թվականին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Low molecular weight protamine ...... eparation and characterization
@ast
Low molecular weight protamine ...... eparation and characterization
@en
Low molecular weight protamine ...... eparation and characterization
@nl
type
label
Low molecular weight protamine ...... eparation and characterization
@ast
Low molecular weight protamine ...... eparation and characterization
@en
Low molecular weight protamine ...... eparation and characterization
@nl
prefLabel
Low molecular weight protamine ...... eparation and characterization
@ast
Low molecular weight protamine ...... eparation and characterization
@en
Low molecular weight protamine ...... eparation and characterization
@nl
P2093
P2860
P3181
P356
P1433
P1476
Low molecular weight protamine ...... eparation and characterization
@en
P2093
P2860
P3181
P356
10.1208/PS030317
P407
P577
2001-01-01T00:00:00Z